AstraZeneca coronavirus trial continues in Brazil, despite enrollee death
The Brazilian arm of AstraZeneca’s (LSE: AZN) Phase III COVID-19 vaccine study will continue, notwithstanding the death of a participant, the country’s health authority ANSIVA said on Wednesday.
It is believed that the enrollee was given a placebo, not the vaccine candidate, AZD1222, and an independent committee has recommended that the trial, which is about 80% enrolled, should continue.
With the US arm of the multi-site study still on hold following a separate incident in September, the continuation of the Brazilian component could be key to the firm’s ambitious timeline for approval and distribution.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze